Detailed Narrative
Robust H1 FY26 Financial Performance
Madhavbaug delivered a strong financial performance in H1 FY26, with revenue from operations growing 19.48% year-on-year to INR 49.94 crores. This growth was primarily fueled by increased patient engagement and robust wellness product sales. The company achieved an EBITDA (excluding other income) of INR 8.62 crores, marking a 49.59% YoY increase, and an EBITDA margin of 17.26%, reflecting improved operational efficiency. Profit after tax also saw a significant rise of 28.26% YoY to INR 4.84 crores, with the PAT margin improving by 66 basis points to 9.68%.
Aggressive Hospital Capacity Expansion
The company is embarking on an ambitious hospital expansion strategy, targeting a total of 1,000 beds nationwide within the next 2-3 years. Immediate plans include increasing capacity at Khopoli to 150 beds, Nagpur to 100 beds, and Vadodara to 100 beds, alongside the existing 20 beds at Vizag, aiming for a total of 350-370 beds within the next 12-15 months. A CAPEX of INR 25-30 crores is allocated for the Khopoli and Nagpur expansions, with an additional INR 55 lakhs for Nagpur and INR 1.8 crores for the newly launched Urja Neuro Care facility, a specialized neuro care center.
First International Foray with Malaysian Joint Venture
Madhavbaug has initiated its first overseas venture by signing a Memorandum of Understanding with Maxura Healthcare in Malaysia. This joint venture aims to establish and manage an Ayurvedic therapy center under the brand Maxura Ayurveda Healthcare. Madhavbaug will contribute its clinical expertise and protocols, while Maxura Healthcare will handle the investment. Profits from this collaboration will be shared in a 30:70 ratio, with Madhavbaug receiving 30% of the total share generated, marking a strategic step towards global recognition.
Clinic Network Growth and Patient Acquisition Strategy
Clinics continue to be a core pillar of Madhavbaug's business, with plans to add 40-50 new clinics in FY26 and another 70-80 in FY27, focusing on Tier 2 and Tier 3 cities. The company expects to attract 1.2-1.3 lakh new patients by the end of FY26, with a medium-term target of 2 lakh new patients annually by FY28. Management highlighted that new patient footfall is the primary growth driver, with each new patient contributing INR 6,000-7,000 in revenue to the company.
Product Innovation and Online Sales Expansion
Madhavbaug is actively scaling up its proprietary product, Madhavprash, aiming to increase sales from the current 15,000-20,000 packs per month to 1 lakh packs per month within the next 24 months. The product is sold through various online platforms, including Amazon, and boasts a 45% repeat purchase rate. The company is also developing new ayurvedic food products, such as protein-rich and low-carb options, which are expected to be launched in the next 4-6 months to cater to a broader market.
Positive Outlook and Main Board Listing Ambitions
The company maintains a positive outlook, guiding for FY26 revenue of INR 115-120 crores, with an EBITDA margin of 17-18% and PAT of 10-11%. For FY27, they anticipate over 20% revenue growth and steadily increasing EBITDA margins. By FY28, Madhavbaug targets a total revenue of INR 250 crores, split equally between clinics and hospitals, with EBITDA margins potentially reaching 30-35%. Furthermore, the company plans to transition from the SME board to the main board within the next 6-7 months, with implementation steps already underway.